BMS adds to Opdivo and Yervoy evidence with double dose of data

Bristol Myers Squibb (NYSE: BMY) has presented two lots of data on its immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

The US pharma major presented five-year results from the first part of the Phase III CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of first-line treatment with the combination compared to chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC), regardless of PD-L1 expression levels.

"We’re seeing the full potential of Opdivo-based regimens to transform the lives of patients with thoracic cancers"Abderrahim Oukessou, BMS vice president, thoracic cancers development lead, said: “Advances in treatment are providing new hope for patients with metastatic lung cancer – a disease with a dismal historical five-year survival rate of approximately 6% if left untreated. With extended follow-up, the results with dual immunotherapy demonstrate impressive durability.